Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline Review, H2 2016’, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)

The report reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) therapeutics and enlists all their major and minor projects

The report assesses Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Clementia Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Heart Metabolics Ltd

La Jolla Pharmaceutical Company

Oncodesign SA

Pfizer Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Overview 6

Therapeutics Development 7

Pipeline Products for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview 7

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics under Development by Companies 8

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Products under Development by Companies 11

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development 12

Clementia Pharmaceuticals Inc 12

Daiichi Sankyo Company Ltd 13

Heart Metabolics Ltd 14

La Jolla Pharmaceutical Company 15

Oncodesign SA 16

Pfizer Inc 17

Regeneron Pharmaceuticals Inc 18

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

LJPC-6417 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

palovarotene - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

perhexiline maleate - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

REGN-2477 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

sirolimus - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones 42

Featured News & Press Releases 42

Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva 42

Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study 43

Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia’s Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP) 43

Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by Clementia Pharmaceuticals Inc, H2 2016 12

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 13

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by Heart Metabolics Ltd, H2 2016 14

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by La Jolla Pharmaceutical Company, H2 2016 15

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by Oncodesign SA, H2 2016 16

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by Pfizer Inc, H2 2016 17

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

List of Figures

List of Figures

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports